Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1884-1892

  Tokunaga, Clayton C ^a   Mitton, Kenneth P ^a   Dailey, Wendelin ^a   Massoll, Charlotte ^a   Roumayah, Kevin ^a   Guzman, Ed ^a   Tarabishy, Noor ^a   Cheng, Mei ^a   Drenser, Kimberly A ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Aflibercept; Anti VEGF; Neurovascular niche; Retinopathy of prematurity; VEGF

Indexed keywords

AFLIBERCEPT; CALRETININ; KETAMINE; PHOSPHATE BUFFERED SALINE; RHODOPSIN; VASCULOTROPIN INHIBITOR; XYLAZINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVASCULAR RETINA; B WAVE; CONTROLLED STUDY; ELECTROGRAPH; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPH; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NEOVASCULAR TUFT; NEWBORN; NONHUMAN; OPTIC DISK; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; RETINA; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION;

AFLIBERCEPT; ANTI-VEGF; NEUROVASCULAR NICHE; RETINOPATHY OF PREMATURITY; VEGF;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FOLLOW-UP STUDIES; MICE; MICE, INBRED C57BL; OXYGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RECOVERY OF FUNCTION; RETINA; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897136309     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13397     Document Type: Article

References (30)

1. Lafuente JV, Ortuzar N, Bengoetxea H, Bulnes S, Argandoña EG. Vascular endothelial growth factor and other angioglioneurins: key molecules in brain development and restoration. Int Rev Neurobiol. 2012;102:317-346.
2. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol. 2007;113:607-626.
3. Siatkowski RM, Dobson V, Quinn GE, Summers CG, Palmer EA, Tung B. Severe visual impairment in children with mild or moderate retinal residua following regressed threshold retinopathy of prematurity. J AAPOS. 2007;11:148-152.
4. Quinn GE, Dobson V, Davitt BV, et al; Early Treatment for Retinopathy of Prematurity Cooperative Group. Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J AAPOS. 2013;17:124-128.
5. Joyal JS, Sitaras N, Binet F, et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood. 2011;118:6024-6035.
6. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(suppl A):S140-S144.
7. Zeng G, Taylor SM, McColm JR, et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood. 2007;109:1345-1352.
8. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 2001;15:1215-1217.
9. Schlingemann RO, van Hinsbergh VW. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol. 1997;81:501-512.
10. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284:21036-21046.
11. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci. 2006; 47:5106-5115.
12. Cai J, Wu L, Qi X, et al. Placenta growth factor-1 exerts timedependent stabilization of adherens junctions following VEGFinduced vascular permeability. PLoS One [serial online]. 2011; 6:e18076. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3064593. Accessed February 12, 2014.
13. Malik S, Vinukonda G, Vose LR, et al. Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth. J Neurosci. 2013;33:411-423.
14. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
15. Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;187:2715-2723.
16. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565-1573.
17. Lukas W, Jones KA. Cortical neurons containing calretinin are selectively resistant to calcium overload and excitotoxicity in vitro. Neuroscience. 1994j;61:307-316.
18. Penn JS, McCollum GW, Barnett JM, Werdich XQ, Koepke KA, Rajaratnam VS. Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2006;47:405-414.
19. Tokunaga CC, Chen YH, Dailey W, Cheng M, Drenser KA. Retinal vascular rescue of oxygen-induced retinopathy in mice by norrin. Invest Ophthalmol Vis Sci. 2013;54:222-229.
20. Ward NL, Lamanna JC. The neurovascular unit and its growth factors: coordinated response in the vascular and nervous systems. Neurol Res. 2004;26:870-883.
21. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature. 2005;436:193-200.
22. Bautch VL, James JM. Neurovascular development: the beginning of a beautiful friendship. Cell Adh Migr. 2009;3: 199-204.
23. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;181:53-67.
24. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygeninduced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;52:4039-4047.
25. James JM, Gewolb C, Bautch VL. Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube. Development. 2009;136:833-841.
26. Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379-1390.
27. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One [serial online]. 2008;3:e3554. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2571983. Accessed February 12, 2014.
28. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A. 2000;97:10242-10247.
29. Brar VS, Sharma RK, Murthy RK, Chalam KV. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis. 2010;16:1848-1853.
30. Nakamura S, Imai S, Ogishima H, Tsuruma K, Shimazawa M, Hara H. Morphological and functional changes in the retina after chronic oxygen-induced retinopathy. PLoS One [serial online]. 2012;7:e32167. Available at: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC3279421. Accessed February 12, 2014.